Resveratrol

A recent resveratrol related study by researchers at the University of California, Merced focused on resveratrol;s effect on inhibiting the growth of lung cancer.

Because resveratrol has anti-inflammatory properties, and the researchers know that prior to tumors growing in lung tissue, inflammation occurs because of the accumulation of toxic free radicals, Resveratrol may have binded with and removed the free radicals.

The scientists were shocked to see that actually resveratrol didn’t remove the free radials, but instead protected the enzymes, called caspasses, that kill off precancerous cells.

This exciting new development will be published in a new paper in the International Journal of Biochemistry & Cell Biology in the upcoming month or two.

Pfizer Inc has had their hired scientists try and debunk resveratrol’s effectiveness and strike a blow at their arch rival, GlaxoSmithKlein, which has over $720 million invested in creating synthetic drugs that mimic resveratrol.

The ‘corporate’ researchers published their study in January in the Journal of Biological Chemistry that questioned previous studies that suggests resveratrol may enhance an enzyme that slows the aging process.

These researchers suggested that resveratrol is not a direct activator of the sirtuin gene or any other biochemical pathway – as if this is simply a linear straightforward process.

The research in the this field seems to be overwelming in favor of resveratrol being beneficial in may aspects for maintaining good health. This could just be another instance of corporate “bad mouthing” and results oriented scientific study that can be easily skewed to show a specific result.

Results from a recently published scientific study display that resveratrol may inhibit the production of protein chunks – called amyloid fibrils. The fibrils – created from beta-amyloid protein – typically combine into the unique plaques generally present in people suffering from Alzheimer’s .

Alzheimer’s disease is a type of dementia that steals people of their ability to recall and execute basic tasks, such as eating and dressing. There are no meds to subdue or correct this tragic and terminal disease.
Preventing the creation of fibrils and unwinding them once they congregate into plaques are the present concentration of efforts to fight this disease that attacks brain organisms. According to the Alzheimer’s Association, over five million people in the United States, alone, suffer from this disease.

The results from the experiment, which was published recently on the internet in the journal Neurotoxicology, concur with previous human epidemiology experiments that associate regular red wine consumption with a reduction in risk of developing dementia.

Scientists studied resveratrol’s effects on fibrils by adding one type of beta-amyloid (Aβ42) with it and then looking for protein aggregation. They discovered that the larger the dosage of resveratrol, the smaller the quantity of aggregation. Resveratrol dramatically decreased the aggregation by as much as ninety percent.
Resveratrol also triggered the beta-amyloid fibrils to break apart, suggesting it may have the probability to destroy plaque that has already formed.

Though amyloid plaques are a unique aspect of Alzheimer’s disease, it is not totally transparent how these plaques foment the dementia associated with the disease. There is some signs that the fibrils that aggregate into the distinctive plaques are not as toxic to the brain than the intermediate compounds called oligomers. Resveratrol didn’t reduce the creation of oligomers, although the researchers saw some evidence that resveratrol could inhibit their toxic affect on cells.

The National Canine Cancer Foundation has awarded Resvantage Canine their Pink Paw Seal of Approval for a “product that helps to advance the holistic health of our pets and helping fight canine cancer.” This designation is granted only to companies who have met rigorous quality standards and other criteria established by their Scientific Advisory Board.

The National Canine Cancer Foundation is a nationwide, contribution funded, 501 (c)(3) non-profit corporation dedicated to eliminating Cancer as a major health issue in dogs by funding grants directly to Cancer researchers who are working to save lives, find cures, better treatments and accurate, cost effective diagnostic methods in dealing with Canine Cancer.

The purpose of the Foundation’s Research Grant Program is to encourage and provide grant support for basic, pre-clinical and clinical research in high impact and innovative cancer research, which is intended to develop innovative approaches to a cure, treatment, diagnosis or prevention of cancers in dogs. The program fosters collaboration between basic and clinical scientists with the intent of enhancing the transfer of basic research findings to clinical usefulness.

Gary D. Nice, the Founder, Director, President and Chief Executive Officer was devastated by the loss of three dogs to Cancer in three years. He found out during those heart wrenching times how much work needed to be done to fight cancer in dogs and how many dogs were dying every day, many prematurely, to cancer. At that point, he decided to dedicate the rest of his life and resources to finding a cure for canine cancer.

He states, “Resvantage Canine is a very promising product as resveratrol has shown efficacy in the prevention and treatment of many different types of cancers and it gives us all hope as we continue to work to find a cure.”